Curcumin,An Atoxic Antioxidant and Natural NFκB,Cyclooxygenase-2,Lipooxygenase,and Inducible Nitric Oxide Synthase Inhibitor: A Shield Against Acute and Chronic Diseases

Abstract

Background: The world suffers a tsunami of chronic diseases, and a typhoon of acute illnesses, many of which are associated with the inappropriate or exaggerated activation of genes involved in inflammation. Finding therapeutic agents which can modulate the inflammatory reaction is the highest priority in medical research today. Drugs developed by the pharmaceutical industry have thus far been associated with toxicity and side effects, which is why natural substances are of increasing interest. Methods: A literature search (PubMed) showed almost 1500 papers dealing with curcumin, most from recent years. All available abstracts were read. Approximately 300 full papers were reviewed. Results: Curcumin, a component of turmeric, has been shown to be non-toxic, to have antioxidant activity, and to inhibit such mediators of inflammation as NFκB, cyclooxygenase-2 (COX-2), lipooxygenase (LOX), and inducible nitric oxide synthase (iNOS). Significant preventive and/or curative effects have been observed in experimental animal models of a number of diseases, including arteriosclerosis, cancer, diabetes, respiratory, hepatic, pancreatic, intestinal and gastric diseases, neurodegenerative and eye diseases. Conclusions: Turmeric, an approved food additive, or its component curcumin, has shown surprisingly beneficial effects in experimental studies of acute and chronic diseases characterized by an exaggerated inflammatory reaction. There is ample evidence to support its clinical use, both as a prevention and a treatment. Several natural substances have greater antioxidant effects than conventional vitamins, including various polyphenols, flavonoids and curcumenoids. Natural substances are worth further exploration both experimentally and clinically.

Turmeric or curcumin shows strong antioxidant and anti-inflammatory effects. Preventive and curative effects are observed in animal studies with induced diseases such as arteriosclerosis, cancer, diabetes, as well as in various respiratory, gastrointestinal, and neurodegenerative diseases and ocular opacities.

Get full access to this article

View all access options for this article.

References

Heffler S, Smith S, Won G, Clemens MK, Keehan S, Zezza M. Health spending projections for 2001–2011: the latest outlook: faster health spending growth and a slowing economy drive the health spending projections for 2001 up sharply. Health Aff (Millwood). 2002 ;21:207– 218.

Bernes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997 ;336:1066– 1071.

Amit S, Ben-Neriah Y. NF-kappaB activation in cancer: a challenge for ubiquitination- and proteasome-based therapeutic approach. Semin Cancer Biol. 2003;13:15– 28.

Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene. 1999 ;18:6853– 6866.

Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase-2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol. 2000 ;164:361– 370.

Sharma RA, Ireson CR, Verschoyle RD, et al. Effects of dietary curcumin on glutathione S-transferase and malonaldehyde-DNA adducts in rat liver and colonic mucosa: relationship with drug levels. Clin Cancer Res. 2001;7:1452– 1458.

Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of peperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998 ;64:1167– 1172.

Bravani Shankar TN, Shantha NV, Ramesh HP, Murthy IA, Murthy VS. Toxicity studies on turmeric (Curcuma longa): acute toxicity studies in rats, guinea pigs and monkeys. Indian J Exp Biol. 1980 ;18:73– 75.

Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of turmeric (Curcuma longa). J Altern Complement Med. 2003;9:161– 168.

10.

Grant KL, Schneider CD. Turmeric. Am J Health Syst Pharm. 2000;57:1121– 1122.

11.

Surh Y-J, Chun K-S, Cha H-H, et al. Molecular mechanisms underlying chemo-preventive activities of anti-inflammatory phytochemicals: downregulation of COX-2 and iNOS through suppression of NF-κB activation. Mutat Res. 2001;243– 268, 480–481.

12.

Dunsmore KE, Chen PG, Wong HR. Curcumin, a medicinal herbal compound capable of inducing the heat shock response. Crit Care Med. 2001;29:2199– 2204.

13.

Chang D-M. Curcumin: a heat shock response inducer and potential cytoprotector. Crit Care Med. 2001 ;29:2231– 2232.

14.

Wallace JM. Nutritional and botanical modulation of the inflammatory cascade—eicosanoids, cyclooxygenases and lipooxygenases—as an adjunct in cancer therapy. Integr Cancer Ther. 2002;1:7– 37.

15.

Began G, Sudharshan E, Udaya Sankar K, Appu Rao AG. Interaction of curcumin with phosphatidylcholine: a spectrofluorometric study. J Agric Food Chem. 1999;47:4992– 4997.

16.

Thapliyal R, Maru GB. Inhibition of cytochrome P450 isoenzymes by curcumins in vitro and in vivo. Food Chem Toxicol. 2001;39:541– 547.

17.

Jovanovic SV, Boone CW, Steenken S, Trinoga M, Kaskey RB. How curcumin preferentially works with water soluble antioxidants. J Am Chem Soc. 2001;123:3064– 3068.

18.

Gaedeke J, Noble NA, Border WA. Curcumin blocks multiple sites of the TGF-β signaling cascade in renal cells. Kidney Int. 2004 ;66:112– 120.

19.

Srinivasan P, Libbus B. Mining MEDLINE for implicit links between dietary substances and diseases. Bioinformatics. 2004 ;20(suppl 1):I290– I296.

20.

Kang BY, Song YJ, Kim KM, Choe YK, Hwang SY, Kim TS. Curcumin inhibits Th1 cytokine profile in CD4⁺ T cells by suppressing interleukin-12 production in macrophages. Br J Pharmacol. 1999 ;128:380– 384.

21.

Fugh-Berman A. Herb-drug interactions. Lancet. 2000 ;355:134– 138.

22.

Groten JP, Butler W, Feron VJ, Kozianowski G, Renwick AG, Walker R. An analysis of the possibility for health implications of joint actions and interactions between food additives. Reg Toxicol Pharmacol. 2000 ;31:77– 91.

23.

Kamal-Eldin A, Frank J, Razdan A, Tengblad S, Basu S, Vessby B. Effects of dietary phenolic compounds on tocopherol, cholesterol and fatty acids in rats. Lipids. 2000 ;35:427– 435.

24.

Shapiro TA, Fahey JW, Wade KL, et al. Human metabolism and excretion of cancer chemoprotective glucoisonolates and isothiocyanates of cruciferous vegetables. Cancer Epidemiol Biomarkers Prev. 1998 ;7:1091– 1100.

25.

Pulla Reddy AC, Sudharshan E, Appu Rao AG, Lokesh BR. Interactions of curcumin with human serum albumin: a spectroscopic study.Lipids. 1999;34:1025– 1029.

26.

Awasthi S, Pandya U, Singhal SS, et al. Curcumin-glutathione interactions and the role of human glutathione S-transferase P1–1.Chem Biol Interact. 2000 ;128:19– 38.

27.

McDowell IFW, Lang D. Homocysteine and endothelial dysfunction: a link with cardiovascular disease. J Nutr. 2000 ;130(suppl 1):369S– 372S.

28.

Tucker KL, Selhub J, Wilson PWF, Rosenberg IH. Dietary intake pattern relates to plasma folate and homocysteine concentrations in the Framingham Heart Study. J Nutr. 1996 ;126:3025– 3031.

29.

Lasheras C, Huerta JM, González S, et al. Diet store is associated with plasma homocysteine in healthy institutionalised elderly population. Nutr Metab Cardiovasc Dis. 2003 ;13:384– 390.

30.

Iannuzzi A, Celentano E, Panico S, et al. Dietary and circulating antioxidant vitamins in relation to carotid plaques in middle-aged women.Am J Clin Nutr. 2002;76:582– 587.

31.

Akhilender Naidu K, Thippeswamy NB. Inhibition of human low density lipoprotein oxidation by active principles from spices. Mol Cell Biochem. 2002;229:19– 23.

32.

Kempaiah RK, Srinivasan K. Integrity of erythrocytes of hypercholesterolemic rats during spices treatment. Mol Cell Biochem. 2002;236:155– 161.

33.

Asai A, Miyazawa T. Dietary corcuminoids prevent high-fat dietinduced lipid accumulation in rat liver and epididymal adipose tissue.J Nutr. 2001;131:2932– 2935.

34.

Quiles JL, Mesa MD, Ramirez-Tortosa CL, et al. Curcuma longa extract supplementation reduces oxidative stress and attenuates aortic fatty streak development in rabbits. Arterioscler Throm Vasc Biol. 2002;22:1225– 1231.

35.

Giltay EJ, Hoogeveen EK, Elbers JM, Gooren LJ, Asscheman H, Stehouwer CD. Insulin resistance is associated with elevated plasma total homocysteine levels in healthy, non-obese subjects [letter].Atherosclerosis. 1998;139:197– 198.

36.

Arun N, Nalini N. Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. Plant Foods Hum Nutr. 2002 ;57:41– 52.

37.

Punithavatihi DP, Venkatesan N, Babu M. Protective effects of curcumin against amimodarone-induced pulmonary fibrosis in rats. Br J Pharmacol. 2003;139:1342– 1350.

38.

Illek B, Lizarzaburu ME, Lee V, Nantz MH, Kurth MJ, Fischer H. Structural determinants for activation and block of CFTR-mediated chloride currents by apigenin. Am J Physiol Cell Physiol. 2000 ;279:C1838– C1846.

39.

Egan ME, Pearson M, Weiner SA, et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science. 2004 ;304:600– 602.

40.

Zeitlin P. Can curcumin cure cystic fibrosis? N Engl J Med. 2004;351:606– 608.

41.

Ram A, Das M, Ghosh B. Curcumin attenuates allergen-induced hyperresponsiveness in sensitized guinea pigs. Biol Pharm Bull. 2003 ;26:1021– 1024.

42.

Rukkumani R, Balasubashini S, Vishwanathan P, Menon VP. Comparative effects of curcumin and photo-irradiated curcumin on alcohol- and polyunsaturated fatty acid-induced hyperlipidemia. Pharmacol Res. 2002;46:257– 264.

43.

Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Thomas P, Dannenberg AJ. Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF-κB-dependent genes. Am J Physiol Gastrointest Liver Physiol. 2003 ;284:G321– G327.

44.

Park E-J, Jeon CH, Ko G, Kim J, Sohn DH. Protective effect of curcumin in rat liver injury induced by carbon tetrachloride. J Pharm Pharmacol. 2000;52:437– 440.

45.

Gukovsky I, Reyes CN, Vaquero EC, Gukovskaya AS, Pandol SJ. Curcumin ameliorates ethanol and nonethanol experimental pancreatitis.Am J Physiol Gastrointest Liver Physiol. 2003 ;284:G85– G95.

46.

Mahady GB, Pendland SL, Yun G, Lu ZZ. Turmeric (Curcuma longa) and curcumin inhibit the growth of Helicobacter pylori, a group 1 carcinogen. Anticancer Res. 2002 ;22:4179– 4182.

47.

Foryst-Ludwig A, Neumann M, Schneider-Brachert W, Naumann M. Curcumin blocks NF-κB and the mitogenic response in Helicobacter pylori-infected epithelial cells. Biochem Biophys Res Com. 2004 ;316:1065– 1072.

48.

Kim M-K, Choi G-J, Lee H-S. Fungal property of Curcuma longa rhizome-derived curcumin against phytopathogenic fungi in greenhouse. J Agr Food Chem. 2003 ;51:1578– 1581.

49.

Rachmilewitz D, Karmell F, Okon F, Bursztyn M. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity.Gut. 1995;37:247– 255.

50.

Ukil A, Maity S, Karmakar S, Datta N, Vedasiromoni JR, Das PK. Curcumin, the major component of food flavour turmeric reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol. 2003;139:209– 218.

51.

van't Land B, Blijlevens NM, Marteijn J, et al. Role of curcumin and the inhibition of NF-κB in the onset of chemotherapy-induced mucosal barrier injury. Leukemia. 2004 ;18:276– 284.

52.

Levi MS, Borne RF, Williamson JS. A review of cancer chemopreventive agents. Curr Med Chem. 2001 ;8:1349– 1362.

53.

Sinha R, Anderson DE, McDonald SS, Greenwald P. Cancer risk and diet in India. J Postgrad Med. 2003 ;49:222– 228.

54.

Choudhuri T, Pal S, Agwarwal ML, Das T, Sa G. Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction.FEBS Lett. 2002;512:334– 340.

55.

Shao Z-M, Shen Z-Z, Liu C-H, et al. Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int J Cancer. 2002;98:234– 240.

56.

Radhakrishna Pillai G, Srivastava AS, Hassanein TI, Chauhan DP, Carrier E. Induction of apoptosis in human lung cancer cells by curcumin.Cancer Lett. 2004;208:163– 170.

57.

Zheng M, Ekmekcioglu S, Walch ET, Tang CH, Grimm EA. Inhibition of nuclear factor–κB and nitric oxide by curcumin induces G₂/M cell cycle arrest and apoptosis in human melanoma cells.Melanoma Res. 2004;14:165– 171.

58.

Han S-S, Keum Y-S, Seo H-J, Surh Y-J. Curcumin suppresses activation of NF-κB and AP-1 induced by phorbol ester in cultured human promyelocytic leukaemia cells. J Biochem Molecul Biol. 2002 ;35:337– 342.

59.

Bharti AC, Shishodia S, Reuben JM, et al. Nuclear factor-κB and STAT3 are constitutively active in CD138⁺ cells derived from myeloma patients and suppression of these transcription factors leads to apoptosis. Blood. 2004;103:3175– 3184.

60.

Liontas A, Yeger H. Curcumin and resveratrol induce apoptosis and nuclear translocation and activation of p53 in human neuroblastoma.Anticancer Res. 2004;24:987– 998.

61.

Elattar TMA, Virji AS. The inhibitory effect of curcumin, genistein, quercetin and cisplatin on the growth of oral cancer cells in vitro. Anticancer Res. 2000 ;20:1733– 1738.

62.

Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene. 2001 ;20:7597– 7609.

63.

Nakamura K, Yasunaga Y, Segawa T, et al. Curcumin down-regulates AR gene expression in prostate cancer cell lines. Int J Oncol. 2002 ;21:825– 830.

64.

Hour T-C, Chen J, Huang C-Y, Guan JY, Lu SH, Pu YS. Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21^WAFI/CIPI and C/EBPβ expressions and suppressing NF-κB activation. Prostate. 2002 ;51:211– 218.

65.

Deeb D, Jiang H, Gao X, et al. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-κB through suppression of IκBα phosphorylation. Mol Cancer Ther. 2004 ;3:803– 812.

66.

Ohashi Y, Tsuchiya Y, Koizumi K, Sakurai H, Saiki I. Prevention of intrahepatic metastasis by curcumin in an orthotopic implantation model.Oncology. 2003;65:250– 258.

67.

Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001 ;21:2895– 2900.

68.

Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci. 2000;20:5709– 5714.

69.

Björkman D. Nonsteroidal anti-inflammatory drug-associated toxicity of liver, lower gastrointestinal tract, and esophagus. Am J Med. 1998;105:17S– 21S.

70.

Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer disease: the Alzheimer Disease Cooperative Study. N Engl J Med. 1997 ;336:1216– 1222.

71.

Zhao BL, Li XJ, He RG, Cheng SJ, Xin WJ. Scavenging effects of green tea and natural antioxidants on active oxygen radicals. Cell Biophys. 1989;14:175– 185.

72.

Sreejavan N, Rao MNA. Nitric oxide scavenging by curcumenoids.J Pharm Pharmacol. 1997;49:105– 107.

73.

Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci. 2001 ;21:8370– 8377.

74.

Frautschy SA, Hu W, Kim P, et al. Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology.Neurobiol Aging. 2001;22:993– 1005.

75.

Ganguli M, Chandra V, Kamboh MI, et al. Apolipoprotein E polymorphism and Alzheimer disease: the Ino-US Cross-National Dementia Study.Arch Neurol. 2000;57:824– 830.

76.

Muthane U, Yasha TC, Shankar SK. Low numbers and no loss of melanized nigral neurons with increasing age in normal human brains from India. Ann Neurol. 1998;43:283– 287.

77.

Joseph JA, Shukitt-Hale B, Denisova NA, et al. Reversals of age-related declines in neuronal signal transduction, cognitive and motor behavioural deficits with blueberry, spinach and strawberry dietary supplementation. J Neurosci. 1999 ;19:8114– 8121.

78.

Rajakrishnan V, Viswanathan P, Rajasekharan N, Menon VP. Neuroprotective role of curcumin from Curcuma longa on ethanol-induced brain damage. Phytother Res. 1999 ;13:571– 574.

79.

Thylefors B. Prevention of blindness: WHO's mission for vision.World Health Forum. 1998 ;19:53– 59.

80.

Ughade SN, Zodpey SP, Khanolkar VA. Risk factors for cataract: a case control study. Indian J Ophtalmol. 1998 ;46:221– 227.

81.

Brian G, Taylor H. Cataract blindness: challenges for the 21st century. Bull World Health Organ. 2001 ;79:249– 256.

82.

Pandya U, Saini MK, Jin GF, Awasthi S, Godley BF, Awasthi YC. Dietary curcumin prevents ocular toxicity of naphthalene in rats.Toxicol Lett. 2000;115:195– 204.

83.

Suryanarayana P, Krishnaswamy K, Redde B. Effects on galactose-induced cataractogenesis in rats. Mol Vision. 2003 ;9:223– 230.

84.

Padmaja S, Raju TN. Antioxidant effects in selenium induced cataract of Wistar rats. Ind J Exp Biol. 2004 ;42:601– 603.

85.

Shishodia S, Potdar P, Gairola CG, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-κB activation through inhibition of IκBα kinase in human lung cancer epithelial cells: correlation with suppression of COX-2, MM-9, cyclin D1.Carcinogenesis. 2003;7:1269– 1279.

86.

King DE, Egan BM, Geesey ME. Relation of dietary fat and fiber to elevation of C-reactive protein. Am J Cardiol. 2003 ;92:1335– 1339.

87.

Campbell TC, Junchi C. Diet and chronic degenerative diseases: perspective from China. Am J Clin Nutr. 1994 ;59(suppl):S1153– S1163.

88.

Knekt P, Kumpulainen J, Järvinen R, et al. Flavonoid intake and risk of chronic diseases. Am J Clin Nutr. 2002 ;76:560– 568.

89.

Ikezoe T, Yang Y, Heber D, Taguchi H, Koeffler HP. PC-SPES: a potent inhibitor pf nuclear factor-κB rescues mice from lipopolysaccharide-induced septic shock. Mol Pharmacol. 2003 ;64:1521– 1529.

90.

Kubota T, Hisatake J, Hisatake Y, et al. PC-SPES: a unique inhibitor of proliferation of prostate cancer cells in vitro.Prostate. 2000;42:163– 171.

91.

Huerta S, Arteaga JR, Irwin RW, Ikezoe T, Heber D, Koeffler HP. PC-SPES inhibits colon cancer growth in vitro and in vivo.Cancer Res. 2002;62:5204– 5209.

92.

Ikezoe T, Chen S, Saito T, et al. PC-SPES decreases proliferation and induces differentiation and apoptosis of human acute myeloid leukemia cells. Int J Oncol. 2003 ;23:1203– 1211.

93.

Garcea G, Jones DJL, Singh R, et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer. 2004 ;90:1011– 1015.

94.

Shim JS, Kim DH, Jung HJ, et al. Hydrazinocurcumin, a novel synthetic curcumin derivate, is a potent inhibitor of endothelial cell proliferation. Bioorg Med Chem. 2002 ;10:2439– 2444.